Valeant Pharmaceuticals To Acquire Sprout Pharmaceuticals
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/30/2026
- Crude Inventory Fell 7.2 Million Barrels Last Week - EIA
- SoFi Technologies (SOFI) Tops Q2 EPS by 1c ; Offers Guidance
- Wall Street closes down sharply after Fed holds rates unchanged
- How will the S&P 500 react to today’s FOMC? JPM lays out the playbook
- Grant Thornton Advisors to buy CBIZ in $5 billion deal, expand US accounting reach
- After-Hours Stock Movers: META, MSFT, CMG, SBUX, CVNA, LRCX, FTNT, QCOM, TDOC
- After-Hours Stock Movers: F, BE, STX, WDC, KLAC, SWKS, NXPI, CSGP, ENPH
- After-Hours Stock Movers: FFIV, CDNS, APLD, RMBS, ESI, SANM
- After-Hours Stock Movers: INTC, AMD, ARM, MXL, EW, DECK
- After-Hours Stock Movers: GOOGL, TSLA, NOW, IBM, TXN, MOH, URI
BMO Capital Remains Bullish on Valeant Pharma (VRX) Following Announced Acquisition of 'Female Viagra' Maker Sprout Pharma
August 20, 2015 11:29 AM EDTBMO Capital reiterated an Outperform rating and $285 price target on Valeant Pharmaceuticals (NYSE: VRX) following the announced acquisition on Sprout Pharmaceuticals. Sprout recently received FDA approval for Addyi (filbanserin) , a non-hormonal pill for the treatment of acquired, generalized hypoactive sexual desire disorder (HSDD), on August 18th. Valeant will pay ~$1 billion... More
